AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
Revenue climbed to $10.1 billion as demand for Repatha and Evenity offset weaker Prolia sales, while Amgen lifted its full-year outlook.
8 Articles
8 Articles
AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
THOUSAND OAKS, Calif., Aug. 4, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2026.
Adams Street tops $5bn for secondaries programme as record deal volumes fuel latest raise
Adams Street Partners has raised more than $5bn for its latest secondaries investment programme, as the private markets investor looks to capitalize on a secondary market that surpassed $200bn of annual transaction volume for the first time last year. The post Adams Street tops $5bn for secondaries programme as record deal volumes fuel latest raise appeared first on AltAssets Private Equity News.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium





